PMID: 20124733Feb 4, 2010Paper

Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome

Journal of Atherosclerosis and Thrombosis
S GotoPeder Jensen

Abstract

A previous phase 2 study of patients undergoing non-urgent PCI treated with SCH530348 plus aspirin and clopidogrel tended to reduce MACE without increased bleeding. This study evaluated the safety of SCH530348 in Japanese patients with NSTE ACS. Subjects (117), in whom PCI was planned, received standard-of-care (aspirin, ticlopidine, and heparin) and were randomized 4:1 to receive either SCH530348 (20 or 40 mg loading dose followed by 1 mg/d or 2.5 mg/d for 60 days) or placebo. The key safety endpoint was TIMI major and minor bleeding in the PCI cohort (n=92). The key exploratory efficacy endpoint was MACE and death within 60 days. Addition of SCH530348 to standard-of-care did not significantly increase the rate of TIMI major and minor bleeding (or non-TIMI bleeding) in the primary cohort. Incidence (non-MACE) and discontinuation of AEs were similar across groups. PCI subjects treated with SCH530348 plus standard-of-care experienced a significant reduction in periprocedural MI compared with standard-of-care alone (16.9% vs 42.9%, respectively; p=0.013). There were no deaths or any other MACE. SCH530348 added to standard-of-care did not result in excess bleeding in Japanese subjects with NSTE ACS but significantly reduced the in...Continue Reading

References

Aug 25, 2001·The New England Journal of Medicine·S YusufUNKNOWN Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Jan 23, 2003·The Journal of Pharmacology and Experimental Therapeutics·Claudia K DerianPatricia Andrade-Gordon
Aug 31, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Pascal MauriceFrançoise Fauvel-Lafeve
Feb 24, 2005·Journal of Atherosclerosis and Thrombosis·Kousuke MarutsukaYujiro Asada
Aug 17, 2005·Journal of Thrombosis and Haemostasis : JTH·S R Coughlin
Sep 6, 2005·Journal of Atherosclerosis and Thrombosis·Qaisar Khan, Jawahar L Mehta
Dec 28, 2006·Proceedings of the National Academy of Sciences of the United States of America·Erik R VandendriesBarbara C Furie
May 3, 2007·JAMA : the Journal of the American Medical Association·Keith A A FoxUNKNOWN GRACE Investigators
May 15, 2007·Circulation Research·Telly A Meadows, Deepak L Bhatt
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Dec 14, 2007·The New England Journal of Medicine·Giovanni Davì, Carlo Patrono
Nov 22, 2008·Circulation Journal : Official Journal of the Japanese Circulation Society·Yoshihisa NakagawaShigetake Sasayama
Jan 31, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Noriko TamuraShinya Goto

❮ Previous
Next ❯

Citations

Feb 9, 2012·European Journal of Clinical Pharmacology·Teddy KosoglouDavid L Cutler
Apr 25, 2012·European Journal of Clinical Pharmacology·Paul StatkevichDavid L Cutler
Apr 6, 2012·European Journal of Clinical Pharmacology·Teddy KosoglouDavid L Cutler
May 15, 2010·Journal of Thrombosis and Thrombolysis·Martin Moser, Christoph Bode
May 31, 2012·Journal of Thrombosis and Thrombolysis·Saurav ChatterjeeDebabrata Mukherjee
Jul 28, 2010·Journal of Cardiovascular Translational Research·Christopher OmbrelloCraig N Morrell
Feb 26, 2013·Journal of Cardiovascular Translational Research·Flavio de Souza Brito, Pierluigi Tricoci
Apr 25, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Dominick J Angiolillo, José Luis Ferreiro
Nov 15, 2011·The New England Journal of Medicine·Pierluigi TricociUNKNOWN TRACER Investigators
Mar 27, 2012·The New England Journal of Medicine·David A MorrowUNKNOWN TRA 2P–TIMI 50 Steering Committee and Investigators
Sep 2, 2010·European Heart Journal·Shinya GotoUNKNOWN J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators
Jun 19, 2012·Circulation·Ahmed Abdel-Latif, Susan S Smyth
Dec 4, 2012·The Journal of Clinical Investigation·Khaled KhoufacheBéatrice Riteau
Nov 10, 2010·Journal of Atherosclerosis and Thrombosis·Akinori SairakuYasuki Kihara
Jun 26, 2014·Drugs·Raewyn M Poole, Shelley Elkinson
Sep 22, 2011·European Journal of Clinical Pharmacology·Teddy KosoglouDavid L Cutler
Dec 14, 2011·Current Cardiology Reports·Sergio LeonardiKenneth W Mahaffey
Dec 21, 2012·Indian Heart Journal·Arun NatarajanKare Tang
Nov 13, 2015·Expert Review of Cardiovascular Therapy·Udaya S TantryPaul A Gurbel
Aug 9, 2011·Expert Opinion on Investigational Drugs·Paul A GurbelUdaya S Tantry
Feb 19, 2016·Thrombosis and Haemostasis·Lisa Gross, Dirk Sibbing
Feb 8, 2016·The American Journal of Cardiology·Abhishek SharmaJonathan D Marmur
Aug 19, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Shinya GotoShu Takagi
Aug 31, 2012·Lancet·Stefan James, Claes Held
Nov 1, 2011·Thrombosis Research·Nicoleta AlexandruAdriana Georgescu
Feb 1, 2011·Pharmacology & Therapeutics·Mark N AdamsJohn D Hooper
Oct 16, 2010·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Yukito ShinoharaPeder Jensen
Sep 26, 2015·Future Cardiology·Francesco FranchiDominick J Angiolillo
Sep 13, 2011·British Journal of Clinical Pharmacology·Antonio Tello-MontoliuDominick J Angiolillo
May 3, 2016·Journal of Pharmacy & Bioallied Sciences·Obamiro Kehinde, Rotimi Kunle
Nov 26, 2013·Journal of the American College of Cardiology·Ori Ben-Yehuda
Sep 20, 2012·International Journal of Cardiology·Charis CostopoulosDiana A Gorog
Nov 26, 2013·Thrombosis Research·Kazuya HosokawaIkuro Maruyama
Jan 7, 2015·Annual Review of Pharmacology and Toxicology·Jeremiah P Depta, Deepak L Bhatt
Feb 1, 2017·Expert Opinion on Drug Metabolism & Toxicology·Jose-Angel Perez-RiveraPablo Ruiz-Perez
Jun 9, 2017·Thrombosis and Haemostasis·Christian WeberEmiel P C van der Vorst
Jun 10, 2017·Thrombosis and Haemostasis·Janina JamasbiWolfgang Siess
Jun 23, 2010·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Gilles Montalescot
Nov 28, 2013·Pharmaceuticals·Eric L Wallace, Susan S Smyth

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.